LUNDBECK-FOUNDATION
5.3.2024 16:31:25 CET | Business Wire | Press release
The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience. This year’s award recognizes the pioneering work of three leading neuroscientists – Professor Larry Abbott at Columbia University (USA), Professor Terrence Sejnowski at the Salk Institute (USA), and Professor Haim Sompolinsky at Harvard University (USA) and the Hebrew University (Israel).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305504553/en/
Credit: The Lundbeck Foundation
Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance. The winners of The Brain Prize 2024 have made pioneering contributions to these scientific areas by uncovering some of the principles that govern the brain’s structure, function, and the emergence of cognition and behaviour.
The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.
Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:
“It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience. The three scientists have applied novel and sophisticated approaches from physics, mathematics, and statistics to study the brain. They have developed vital tools for the analysis of highly complex datasets acquired by modern day experimental neuroscientists.
The three prize winners have also proposed conceptual frameworks for understanding some of the brain’s most fundamental processes such as learning, memory, perception and how the brain generates maps of the external world. They have also provided crucial new insights into what may go awry in several devastating disorders of the nervous system, such as epilepsy, Alzheimer’s disease, and schizophrenia. In addition, their scientific achievements have paved the way for the development of brain-inspired artificial intelligence, one of the emerging and transformational technologies of our time.”
On behalf of the Lundbeck Foundation, CEO Lene Skole extends her warmest congratulations to each of the three Brain Prize recipients:
“Their pioneering research has created trailblazing knowledge and paved the way for other scientists to better understand critical brain functions, also in relation to diseases. It aligns fully with our purpose of bringing discoveries to lives. Each of their scientific endeavours began in the 70’s, and their determination, courage and persistence over decades should serve as inspiration for other scientists, and indeed be rewarded.”
FACTS
The human brain consists of approximately 100 billion neurons connected by trillions of synaptic connections. Every function the brain performs relies on the flow of information through these staggeringly complex networks of neurons. A fundamental goal of neuroscience is to understand how these networks are wired together, and how the patterns of neural activity within them give rise to cognition and behaviour. The sheer complexity of the brain means that understanding its language requires theoretical and computational approaches.
Theoretical and computational neuroscience uses mathematics, computer science, theoretical analysis, and abstractions of the brain to understand the principles that govern its structure, how it processes information, generates behaviour, and gives rise to cognitive abilities as perception, imagination, intelligence, the formation of knowledge, memory, problem-solving, decision-making, and the production of language. The field has laid the foundations for the development of AI - one of the most revolutionary developments in modern science.
MORE INFO
Find out more – see the information pack of The Brain Prize 2024 >>
About The Brain Prize
The Brain Prize is the world’s largest neuroscience research prize, and it is awarded each year by the Lundbeck Foundation. The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research. Recipients of The Brain Prize may be of any nationality and work in any country in the world. Since it was first awarded in 2011, The Brain Prize has been awarded to 47 scientists from 10 ten different countries. The Brain Prize recipients are presented with their award by His Royal Highness, King Frederik of Denmark, at a ceremony in the Danish capital, Copenhagen.
About the Lundbeck Foundation
The Lundbeck Foundation is an enterprise foundation encompassing a comprehensive range of commercial and philanthropic activities – all united by its strong purpose; Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner of several international healthcare and medtech companies – Lundbeck, Falck, ALK, Ellab, and Ferrosan Medical Devices – and an active investor in business, science and people through its commercial investments in the financial markets; in biotech companies based on Danish research and through philanthropic grants to science talents and programmes in Danish universities. The Foundation’s philanthropic grants amount to more than DKK 500m annually primarily focusing on the brain – including the world’s largest personal prize awarded in neuroscience, The Brain Prize.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305504553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
